Biography
2010.09--Currently, Department of Physiology, Xuzhou Medical University
2017.09--2019.05, The University of Texas Health Science Center at San Antonio, US, Visiting scholar
Education
2016.09--2019.06, Nanjing Medical University, Physiology, PhD. supervisor: Yuguang Shi
2007.09--2010.06, Xuzhou Medical University, Biochemistry and Molecular Biology, Master, supervisor: Xiaoyu Hou
1999.09--2004.06, Xuzhou Medical College, Clinical Medicine, Bachelor degree
Funds
1. National Natural Science Foundation of China projects/topics chaired or participated in over the past five years:
(1) National Natural Science Foundation of China, General Program, Molecular and circuit mechanisms of the involvement of GABA neurotransmitter homeostasis imbalance in neural synapses mediated by astrocytes in the zona incerta in postoperative anxiety. 2024.01.01 - 2027.12.31, ¥490,000, in progress, participated.
(2) National Natural Science Foundation of China, General Program, 82171199, Abnormal lactate levels from aerobic glycolysis in astrocytes mediate cognitive impairment in Alzheimer's disease through NMDA receptors, 2022.01.01 - 2025.12.31, ¥550,000, in progress, participated.
(3) National Natural Science Foundation of China, General Program, 31771309, Research on the mechanism of cardiolipin remodeling enzyme ALCAT1 regulating mitochondrial dysfunction and metabolic diseases, 2018.01.01 - 2021.12.31, ¥600,000, completed, participated.
2. Other scientific research projects/topics (excluding National Natural Science Foundation of China projects) chaired or participated in over the past five years:
(1) Jiangsu Provincial Natural Science Foundation, General Program, BK20231182,
Research on the role and mechanism of ALCAT1 in Parkinson's disease through regulating the inflammatory response mediated by mitochondrial DNA, 202309-202608. ¥100,000, in progress, chaired.
(2) Jiangsu Provincial Department of Human Resources and Social Security, Class C project of Jiangsu Postdoctoral Research Funding Program, RC5052003, Exploring the mechanism of cardiolipin remodeling enzyme in preventing and treating PD based on microglia, 2020.12 – present, ¥20,000, in progress, chaired.
(3) Jiangsu Provincial Department of Science and Technology, Open Project of Jiangsu Provincial Key Laboratory, JSKLCCM-2021-02-004, Research on the mechanism of inflammatory response caused by mitochondrial damage of astrocytes in septic encephalopathy mediated by ALCAT1, 2022.06 – 2024.06, ¥50,000, completed, chaired.
Publications
Representative publications:
1. Liu Xueling, Zhang Jun, Li Jie, Song Chengjie, Shi Yuguang. Pharmacological inhibition of ALCAT1 mitigates amyotrophic lateral sclerosis by attenuating SOD1 protein aggregation. Molecular Metabolism, 2022, 63. 101536.
2. Jiao Yang, Zheng Yue, Song Cheng-Jie*. Protective effect of edaravone on balance of mitochondrial fusion and fission in MPP+-treated PC12 cells, Acta Physiologica Sinica, April 25, 2020, 72(2): 249–254.
3. Chengjie Song, Jun Zhang, Shasha Qi, Zhen Liu, Xiaoyang Zhang, Yue Zheng, John-Paul Andersen, Weiping Zhang, Randy Strong, Paul Anthony Martinez, Nicholas Musi, Jia Nie, Yuguang Shi*, Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson’s diseases, Aging Cell, 2019, 18(3): e12941.
4. Gao Jin#, Qin Dengli, Tang Chuanxi, Kang Xiaoyu, Song Chengjie#, Zhang Cantang*, Smarcd1 antagonizes the apoptosis of injured MES23.5 DA cells by enhancing the effect of Six2 on GDNF expression, Neuroscience Letters, 2021, 760(135088): 0 – 136088.
